在此,一种新的同熔混合阴离子化合物 Cs 4 B 4 O 3 F 10已被表征为第一个具有 [BF 4 ] 的含杂阴离子单元的氟代硼酸盐。化合物Cs 4 B 4 O 3 F 10具有两个高度氟化的阴离子簇,因此其分子式可以表示为Cs 3 (B 3 O 3 F 6 ) ⋅ Cs(BF 4 )。基于母体化合物讨论了[BF 4 ]单元对微对称性和结构演化的影响。更重要的是,Cs 4B 4 O 3 F 10在所有可用的硼酸盐中显示出最低的熔点,从而为此类系统创造了新的记录。这项工作对于使用全氟化 [BF 4 ] 单元丰富和定制硼酸盐的结构具有重要意义。
[EN] THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE<br/>[FR] INHIBITEURS THIOPHÈNES DE LA SÉRINE-THRÉONINE PROTÉINE KINASE IKK-?
申请人:CHROMA THERAPEUTICS LTD
公开号:WO2010122294A1
公开(公告)日:2010-10-28
The invention provides a compound which is (a) a thiophene carboxamide derivative of formula (IA) or (IB), or a tautomer thereof; or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof, wherein L1, A1 and W are as defined herein. The compounds are useful as IKKβ inhibitors. The compounds can thus be used in medicine, for example in the treatment of autoimmune and inflammatory diseases.
Cs
<sub>4</sub>
B
<sub>4</sub>
O
<sub>3</sub>
F
<sub>10</sub>
: First Fluorooxoborate with [BF
<sub>4</sub>
] Involving Heteroanionic Units and Extremely Low Melting Point
作者:Ming Xia、Miriding Mutailipu、Fuming Li、Zhihua Yang、Shilie Pan
DOI:10.1002/chem.202101321
日期:2021.7.7
Herein, a new congruently melting mixed-anion compound Cs4B4O3F10 has been characterized as the first fluorooxoborate with [BF4] involving heteroanionic units. Compound Cs4B4O3F10 possesses two highlyfluorinated anionic clusters and therefore its formula can be expressed as Cs3(B3O3F6) ⋅ Cs(BF4). The influence of [BF4] units on micro-symmetry and structural evolution was discussed based on the parent
在此,一种新的同熔混合阴离子化合物 Cs 4 B 4 O 3 F 10已被表征为第一个具有 [BF 4 ] 的含杂阴离子单元的氟代硼酸盐。化合物Cs 4 B 4 O 3 F 10具有两个高度氟化的阴离子簇,因此其分子式可以表示为Cs 3 (B 3 O 3 F 6 ) ⋅ Cs(BF 4 )。基于母体化合物讨论了[BF 4 ]单元对微对称性和结构演化的影响。更重要的是,Cs 4B 4 O 3 F 10在所有可用的硼酸盐中显示出最低的熔点,从而为此类系统创造了新的记录。这项工作对于使用全氟化 [BF 4 ] 单元丰富和定制硼酸盐的结构具有重要意义。
THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE
申请人:Drummond Alan Hastings
公开号:US20120035251A1
公开(公告)日:2012-02-09
The invention provides a compound which is (a) a thiophene carboxamide derivative of formula (IA) or (IB), or a tautomer thereof; or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof, wherein L
1
, A
1
and W are as defined herein. The compounds are useful as IKKβ inhibitors. The compounds can thus be used in medicine, for example in the treatment of autoimmune and inflammatory diseases.